Blog
Pharma Layoffs and H-1B: New Jersey's Drug Corridor
August 27, 2026
When you cross-reference WARN layoff notices against H-1B sponsors, the sector on top isn't tech — it's pharma and biotech, concentrated in New Jersey. Part 2 of our Layoffs × H-1B series.
When people picture layoffs at companies that hire foreign workers, they picture tech. But when we cross-reference public WARN layoff notices against the list of employers that have filed H-1B paperwork, the sector at the very top of the table is not software — it is pharmaceuticals and biotech, and its center of gravity is a single state: New Jersey.
This is Part 2 of our Layoffs × H-1B series. Part 1 looked at how the two public records fit together at all. Here we zoom in on the drug corridor. All figures below come from the August 2026 snapshot of this site's WARN cross-reference, and cover only the states we track (California, Texas, New Jersey, Illinois, Massachusetts, and Virginia).
Before the numbers, one guardrail that governs this entire piece: a WARN notice never says which workers were laid off. It reports that an employer filed a mass-layoff notification. Whether any H-1B worker was affected is not in the record. Layoffs and LCA filings are two separate public datasets that happen to share an employer name. Nothing here is a causal claim.
The most-noticed sponsor on record is a drugmaker
The single most-noticed H-1B sponsor in our WARN archive is Novartis Pharmaceuticals: 35 separate notices covering roughly 3,904 workers, every one of them filed in New Jersey. For context, Novartis has 889 LCA filings on record — so this is a company with a real, sustained H-1B footprint that also shows up repeatedly in the layoff data.
It is not alone. The corridor's biggest names cluster tightly:
| Employer | WARN notices | Workers (approx.) | State(s) |
|---|---|---|---|
| Novartis Pharmaceuticals | 35 | 3,904 | NJ |
| Johnson & Johnson | 6 | 1,517 | NJ |
| Merck | 11 | 1,421 | NJ |
| Takeda | 8 | 1,187 | IL, MA |
| Novo Nordisk | 1 | 811 | NJ |
| PTC Therapeutics | 2 | 402 | NJ |
Novo Nordisk is worth a note: a single New Jersey notice for roughly 811 workers, effective September 2025. That is one filing carrying nearly as many affected workers as some companies' entire multi-year notice history — a reminder that notice count and worker count tell different stories. Eleven small Merck notices and one large Novo Nordisk notice are not the same event, even though both are "on the table."
Why New Jersey dominates — and the honest caveat
New Jersey leads every state we track for sponsor-linked layoff activity: 346 notices covering roughly 47,674 workers across 190 distinct H-1B sponsors. No other tracked state comes close on cumulative totals.
But that headline deserves an asterisk, and we'd rather give it to you than let you draw the wrong conclusion. New Jersey's WARN archive goes back to 2004 — the deepest history of any state we track. Several other states are only covered from 2019, 2020, or 2021. So part of New Jersey's lead is simply that we have fifteen more years of its records. A state observed for two decades will always accumulate more notices than one observed for five years, all else equal.
What the long archive does legitimately show is concentration. New Jersey is the historic home of Big Pharma's US operations, and both records reflect that: it is where the drug companies file their H-1B labor condition applications, and it is where they file their layoff notices when a pipeline stalls or a merger consolidates sites. The overlap is a geography story as much as a workforce story.
If you want to explore the underlying notices yourself, they live on the layoffs tracker.
Massachusetts: the biotech-bust counterpoint
New Jersey is legacy pharma. Massachusetts is the other pattern entirely — a venture-funded biotech cluster where the layoffs read like a roll call of clinical-stage companies hitting trial or funding walls.
Across the state we count 25 pharma, bio, and therapeutics employers with notices, covering roughly 4,216 workers. These are smaller companies than the New Jersey giants, but the churn is dense:
| Massachusetts biotech employer | Workers (approx.) | Note |
|---|---|---|
| Sage Therapeutics | 502 | |
| Sarepta Therapeutics | 493 | July 2025 |
| Akebia Therapeutics | 181 | |
| Apellis Pharmaceuticals | 175 | |
| Seres Therapeutics | 162 | |
| Vor Biopharma | 155 | |
| Mersana Therapeutics | 124 |
The contrast is the point. New Jersey's totals are driven by a handful of very large employers filing many notices over many years. Massachusetts's totals are driven by many mid-size biotechs each shedding a few hundred people in a compressed window. Same sector, two completely different shapes of risk for a worker weighing an offer.
Where this sits among all tracked states
To see how the pharma-heavy states rank against the rest of the country's H-1B activity, it helps to step back from layoffs and look at raw sponsorship volume. The chart below draws the top states live from the H-1B/LCA data — a useful sanity check on which states even have the sponsor density for a story like this.
New Jersey punches well above its population in H-1B filings, which is exactly why its layoff-and-sponsor overlap is so visible. The state's filing activity and its WARN history point at the same industry.
How to read all of this without over-reading it
If you are a worker in the corridor — or considering a role there — here is how to use these numbers responsibly.
- A notice on a sponsor is not a verdict on the sponsor. Novartis has 889 LCA filings and 35 WARN notices; those are two facts about a large, long-lived employer, not evidence that its visa workers were the ones let go.
- Count vs. headcount matters. Eleven Merck notices is a pattern of repeated smaller actions; one Novo Nordisk notice for ~811 is a single large event. Read both columns, not just one.
- Watch the archive window. New Jersey's totals reflect 20+ years of records; a state tracked only since 2021 will look "quieter" partly because it is younger in the data, not necessarily safer.
- Remember the vocabulary. An LCA is not a visa. A certification rate is not a USCIS approval rate. A withdrawn application is not a denied one. And an offered wage on an LCA is not take-home pay. FY2026 figures are partial — only about two quarters have been reported so far.
The useful takeaway is directional, not deterministic: if you are benchmarking a pharma or biotech offer, the sector's layoff history is concentrated, public, and legible. Look at the specific employer's notice history and its LCA record side by side, understand that neither predicts your individual outcome, and factor the shape of the risk — legacy-giant vs. clinical-stage — into how you weigh the wage.
Next in the series, we turn to the tech sector everyone assumed would top this list, and ask why it doesn't. In the meantime, you can browse the full layoffs tracker or read any employer profile to see filings and notices together.
- pharma layoffs 2026
- H-1B sponsors
- New Jersey
- WARN notices
- biotech layoffs